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ABSTRACT 
Natural killer T (NKT) cells are a subset of T 
lymphocytes that recognize glycolipid antigens 
presented by CD1d molecule (CD1d). They rapidly 
respond to antigen challenge and can activate both 
innate and adaptive immune cells. To study the role 
of antigen presentation in NKT cell activation, 
previous studies have developed several anti-CD1d 
antibodies that block CD1d binding to T-cell 
receptors (TCRs). Antibodies that are specific to 
both CD1d and the presented antigen can only be 
used to study the function of only a limited number 
of antigens. In contrast, antibodies that bind CD1d 
and block TCR binding regardless of the presented 
antigen can be widely used to assess the role of 
TCR-mediated NKT cell activation in various 
disease models. Here, we report the crystal 
structure of the widely used anti-mouse CD1d 
antibody 1B1 bound to CD1d at a resolution of 
2.45Å and characterized its binding to CD1d-
presented glycolipids. We observed that 1B1 uses a 
long hydrophobic H3 loop that is inserted deep into 
the binding groove of CD1d where it makes 
intimate non-polar contacts with the lipid backbone 
of an incorporated spacer lipid. Using an NKT cell 
agonist that has a modified sphingosine moiety, we 
further demonstrate that 1B1 in its monovalent 
form cannot block TCR mediated NKT cell 
activation, since 1B1 fails to bind with high affinity 
to mCD1d.  Our results suggest potential limitations 
of using 1B1 to assess antigen recognition by NKT 
cells, especially when investigating antigens that do 
not follow the canonical two-alkyl-chain rule.
 
 
Besides a role in immunotherapies, 
antibodies that block receptor-ligand interactions 
are often used to assess the importance of a specific 
signaling axis in immune activation or inhibition. 
Receptor-ligand interactions can be complex and 
often involve more than two molecules. For 
example, T cells use their antigen receptor (TCR) 
to recognize the ligand, which forms a composite 
epitope formed by the antigen-presenting molecule 
Major Histocompatibility Complex (MHC) and the 
small antigen that it presents (1). Therefore, 
antibodies that block TCR engagement of MHC 
molecules ideally have an overlapping binding site 
with the TCR on the MHC molecule.  Antibodies 
that block TCR mediated T cell activation exist for 
all MHC molecules including MHC class I (2-5), 
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MHC class II (6), and CD1d (7-9) and are widely 
used to study or modulate T cell function by 
specifically blocking antigen-mediated TCR 
activation. While some antibodies are specific for 
the MHC molecule and the antigen, such as the 
NKT cell antigen receptor blocking antibody L363 
that recognizes mouse (m)CD1d presenting a-
galactosylceramide (aGalCer), the anti-mCD1d 
antibody 1B1 binds to mCD1d regardless of the 
presented antigen (9).  
Natural Killer T (NKT) cells are a 
population of T lymphocytes that recognize 
glycolipid antigens presented by the non-classical 
MHC I homolog CD1d. NKT cells are activated 
within hours after antigen-stimulation and rapidly 
produce both pro- and anti-inflammatory cytokines 
(10). Type I and Type II NKT cells are the major 
classes of NKT cells, and they differ in both their 
TCR usage and their antigen-specificity (11). Type 
I NKT cells express a semi-invariant ab T cell 
receptor (TCR) alpha chain (Va14Ja18 in mouse, 
Va24Ja18 in humans) that pairs with a limited 
number of TCR b chains (Vb8.2, and to a lesser 
extend Vb7 and Vb2 in mouse, Vb11 in human) 
(10,12). The prototypical antigen a-
galactosylceramide (aGalCer) is the common 
antigen for Type I NKT cells (13). Type II NKT 
cells do not have a conserved TCR rearrangement 
and do not recognize a common antigen, making 
them difficult to identify and characterize. While 
Type II NKT cells can recognize a variety of 
different antigens, a well-characterized and major 
subset recognizes sulfatide self-antigens (14-17).  
In addition to Type I and Type II NKT 
cells, minor subsets of unconventional NKT cells 
have also been identified and structurally 
characterized. While these NKT cells exhibit 
specificity toward aGalCer, or related glycolipids 
the TCR repertoire is markedly different from the 
conventional Type I NKT cells (18,19).  
 
Glycolipids are bound by CD1d with the 
lipid backbone deeply inserted into a hydrophobic 
binding groove that is composed of two major 
pockets, A´ and F´. Each pocket accommodates one 
alkyl chain of a dual alkyl chain lipid. For 
ceramide-based lipids, such as aGalCer or 
sulfatide, the acyl chain is accommodated in the 
larger A´ pocket, while the sphingosine moiety is 
bound in the F´ pocket (20-22). The binding 
orientation of diacylglycerolipids is less restricted 
and the sn-1 and sn-2 linked acyl chain can go in 
either of the two pockets, depending on number and 
positions of unsaturations located within the fatty 
acyl chains (23-28). The different headgroups of the 
various glycolipids are exposed at or above the 
CD1d binding groove for TCR recognition.  
 
NKT cells generally recognize the exposed 
headgroup and a few polar groups of the lipid 
backbone. Type I NKT cells maintain a conserved 
binding footprint centered over the F´ pocket of 
CD1d, while the sulfatide-restricted Type II NKT 
cell clone XV19 binds over the A´ pocket (29-33). 
Both TCRs contact their antigens from the side with 
only one chain, TCRa for Type I and TCRb for 
Type II NKT cells. There is no overlap in the 
mCD1d binding footprint between Type I NKT 
cells and the XV19 Type II NKT cell clone. The 
anti-mCD1d antibody 1B1 is able to block both 
TCR mediated activation of Type I and Type II 
NKT cells (ref), suggesting it has an overlapping 
binding site with the TCRs from both NKT cell 
subsets. However, since the glycolipid is presented 
in the center of the CD1d binding groove between 
both TCR binding sites this raises the questions as 
to how 1B1 is able to bind mCD1d and compete 
with both TCRs, while not being impacted by the 
presented glycolipid.  
In order to understand how 1B1 binds to mCD1d 
and blocks both Type I and Type II NKT cell 
activation, we assessed the binding of 1B1 to CD1d 
presenting different glycolipids using Surface 
Plasmon Resonance studies. We have further 
assessed the ability of 1B1 Fab and 1B1 IgG in 
blocking Type I and Type II NKT cell responses 
toward different lipid antigens and determined the 
crystal structure of 1B1 Fab bound to mCD1d at a 
resolution of 2.45Å.  
 
RESULTS 
Generation of 1B1 Fab and mCD1d for 
structural studies-We have generated 1B1 Fab by 
papain digestions and formed complexes with 
insect cell expressed mCD1d that was either loaded 
with a-GalCer or not incubated with a particular 
lipid. While we were able to obtain crystals of the 
complex, we were not able to obtain a diffraction 
dataset beyond 3.9 Å. Therefore, we have generated 
1B1 Fab recombinantly in SF9 insect cells, to limit 
heterogeneity introduced during the papain 
digestion. We have further generated mCD1d via 
refolding to avoid the presence of N-linked glycans. 
Since mCD1d contains an unpaired cysteine at the 
bottom of the A´ pocket (Cys12), we first replaced 
this residue against serine (mCD1d C12S).  We 
formed complexes of all possible combinations of 
the 4 proteins (2 Fab and 2 mCD1d) and finally 
obtained high quality diffracting crystals for the 
  Structure of the mouse CD1d/1B1-Fab complex 
 3 
complex consisting of refolded mCD1d and the 
insect cell expressed 1B1 Fab.  
 
1B1 Fab-mCD1d crystal structure-To determine 
the structural basis of how 1B1 blocks NKT cell 
activation, we have determined the crystal structure 
of the 1B1 Fab/mCD1d complex to 2.45Å 
resolution (Table 1, Fig. 1). CD1d forms the typical 
heterodimeric arrangement in which the CD1d 
heavy chain non-covalently associates with b2-
microglobulin. However, since CD1d has been 
refolded, no N-linked glycans are present in the 
structure. In addition, during the course of 
refolding, three spacer molecules have been 
incorporated into CD1d to stabilize the 
hydrophobic pocket. Two molecules are 
incorporated into the larger A´ pocket and one into 
the F´ pocket of CD1d (Figure 1). Based on the 
extent of the observed electron density, we modeled 
three C16 alkyl chains, which mimic the position of 
the alkyl chains generally associated with 
glycolipid antigens (Figure 2).  
The 1B1 Fab binds perpendicular across 
the lipid binding groove of mCD1d, centered above 
the F´ pocket. The majority of contacts are formed 
between the H chain and CD1d. The H chain uses 
575 Å2 and the L chain 45 Å2 of protein surface and 
together they contact 610 Å2 of CD1d (Table 2). A 
single contact is formed between CDR L1 residue 
Tyr31 and CD1d Glu83, while the H chain binding 
is dominated by hydrophobic contacts (Table 3). 
Only H2 and H3 participate in CD1d binding and in 
together they form three hydrogen bonds and two 
salt bridges. H2:Asp55 forms both a salt bridge and 
H bond with Lys148 of CD1d, while H3:Arg109 
forms a salt bridge with Asp 80 of CD1d, 
H3:Gly105 a H bond with Asp153, and Leu106 a H 
bond with Asp80. A characteristic feature of the 
interaction between 1B1 Fab and CD1d is an 
elongated H3 loop that inserts into the F´ pocket of 
CD1d like a hydrophobic finger and forms many 
hydrophobic contacts with surrounding CD1d 
residues (Fig 1 and 2, Table 3). The H3 loop has 
two tyrosine residues (Tyr103 and Try104) that 
extend outward and slightly upwards from this 
finger and together appear to dictate how far the 
loop inserts into the binding groove of CD1d 
(Figure 2B).  Surprisingly, the H3 loop also is in 
close contact with one of the spacer molecules that 
mimics the position of the sphingosine chain of 
glycolipids, such as sulfatide or a-GalCer (Figure 
2). H3:Tyr104, Gly105, and Leu106 each form one 
VDW contact with the spacer lipid, but the overall 
intimate binding position of H3 leads to a combined 
total buried surface interface of 212 Å2.  
 
1B1 Fab binding kinetics- When we 
superimpose the 1B1/mCD1d complex with that of 
mCD1d/sulfatide (PDB ID 2AKR (20)), we notice 
that the H3 loop of 1B1 is very close to sulfatide, 
especially to the C4”-OH of the galactose (Figure 
2B).  Therefore, we wanted to test the impact of 
1B1 binding to CD1d that presents glycolipids with 
different sizes of headgroups. We chose sulfatide 
and GT1b as model antigens, since they are 
negatively charged and their loading efficiency can 
be visualized. Since 1B1 binds to CD1d without 
presenting a given lipid, we needed to achieve a 
near to 100% loading efficiency to avoid having an 
overlapping binding response contributed by 
unloaded CD1d molecules. After glycolipid 
loading, both sulfatide and GT1b bind to 100% to 
CD1d (Figure 2C) and we used these complexes for 
surface plasmon resonance studies with the 1B1 
Fab (Figure 3D). However, the binding affinity of 
1B1 to mCD1d is nearly identical in all three 
analyzed CD1d-lipid complexes, suggesting that 
variations in the glycolipid headgroups can be 
accommodated by 1B1 and do not affect its binding 
affinity toward CD1d. 1B1 Fab binds with a KD of 
~12.5 nM calculated from an association rate (kon) 
of 5.4-6.1 x 105 and a dissociation rate (koff) of 6.2-
7.3 x 10-3 (Figure 2C).  
 
Comparison between 1B1 and the TCR of 
iNKT cells- When we compared the binding site of 
1B1 with that of the Va14Vb8.2 TCR of iNKT 
cells, we noticed a similar footprint on CD1d 
(Figure 1E, 3, and 4). While 1B1 binds 
perpendicular across the F´ pocket of CD1d, the 
TCR binds parallel along both a-helices (Figure 
1E). In addition, while TCR binding seems to be 
dominated by the CDR3a region, 1B1 uses its 
elongated H3 loop to form the majority of contacts. 
In both molecules, a hydrophobic finger, Leu99a of 
the TCR and Leu106H of the antibody, binds at the 
F´ pocket of CD1d. In striking contrast, however, 
1B1 inserts its hydrophobic finger much deeper into 
the F´ pocket, compared to the TCR (Figure 3A). 
That results in a different binding mode. While the 
TCR sits above the F´ pocket and binds to the F´ 
roof, the antibody prevents F´ roof formation and 
instead sits as a wedge inside the F´ pocket (Figure 
2 B-D). In fact, CDR3a of the TCR flattens out at 
the tip and hovers above CD1d, while the H3 loop 
is straight and reaches into the CD1d binding 
groove (Figure 3C, D). The deep location of the H3 
loop raises the question as to whether the nature of 
the lipid chain that is bound inside the F´ pocket can 
impact 1B1 binding. While common dual alkyl-
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chain based lipids, such as a-GalCer are nestled 
underneath Leu106H of 1B1, lipids containing 
modifications could potentially impact 1B1binding. 
We chose a modified lipid aGSA[26,P5p], and 
superimposed its crystal structure (PDB ID 6C6F) 
with the CD1d/1B1 structure. Leu106H is very close 
to the phenyl group contained in the modified 
sphingamide chain (2.4Å). 
 
1B1 blocking of Type I and Type II NKT cell 
activation- We then analyzed the ability of 1B1 
(both Fab and IgG) to block NKT cell activation by 
various glycolipids. We loaded antigens for both 
Type I and Type II NKT cells into mCD1d and 
performed a NKT cell hybridoma activation assay 
using the NKT hybridomas 1.2 (Type I) and XV19 
(Type II) in the presence or absence of the TCR 
blocking antibody 1B1 (Figure 4). A 1B1 dose 
titration demonstrated that the activation of both 
Type I and Type II NKT cells by a-GalCer and 
sulfatide can be fully blocked with both 1B1 Fab 
and 1B1 IgG. 1B1 Fab appears to block Type I NKT 
cell activation at a lower dose (15.6 µg/ml) 
compared to Type II NKT cells (100 µg/ml), while 
1B1 IgG blocks both hybridoma activation at the 
lowest dose used in this assay (1.5 µg/ml, 
equivalent to equimolar ratio with CD1d). Using a 
structure-guided approach, we generated the 1B1 
Fab Y103K/I56S double mutant, which does not 
bind mouse or human CD1d (Figure 2). The 1B1 
mutant is unable to block NKT cell activation as 
expected (Figure 4). However, using the modified 
sphingamide antigen aGSA[26,P5p], we noticed 
that 1B1 Fab is unable to block NKT cell activation, 
suggesting that the 1B1 binding affinity to mCD1d 
is greatly reduced when aGSA[26,P5p] is bound, 
due to steric clashes with the elongated H3 loop and 
the phenyl moiety of the ligand. Since we could not 
load aGSA[26,P5p] to mCD1d at 100%, we were 
unable to precisely measure the 1B1 binding 
kinetics via SPR. Our data suggests the reduced 
binding affinity drops below a threshold necessary 
for blocking NKT cell responses. This is evident 
when using 1B1 IgG, which in its natural bivalent 
form has an increased binding avidity. 1B1 IgG is 
fully able to block NKT cell activation by 
aGSA[26,P5p]. This demonstrated that while 
common NKT cell antigens can be blocked by 1B1, 
one must be mindful when using 1B1 to block NKT 
activation of structurally diverse glycolipids, such 
as cholesterol antigens or hydrophobic peptides, 
which do not follow the dual alkyl chain rule.  
 
DISCUSSION 
In this study we have determined the crystal 
structure of the 1B1 Fab bound to mouse CD1d. 
1B1 binds to mCD1d in a perpendicular binding 
orientation across the F’ pocket, directly 
overlapping with the binding site of the TCR of 
iNKT cells but with minimal overlap with the 
binding site of the Type II NK TCR clone XV19 
that binds above the A´ pocket of CD1d (31,34-37). 
Nevertheless, 1B1 blocks TCR mediated activation 
of both Type I and Type II NKT cells, as 1B1 
overlaps with XV19 TCR in the central region 
between the A´ and F´ pocket. 1B1 is more potent 
in inhibiting Type II NKT cell responses correlating 
with a greatly reduced binding affinity of the XV19 
TCR compared to the Va14Vb8.2 TCR of Type I 
NKT cells. The XV19 TCR binds with micromolar 
affinity (KD=6-24 µM) to CD1d-sulfatide, while the 
Va14Vb8.2 TCR binds with a KD of 10-30 nM to 
CD1d-aGalCer complexes (28,30,32,33). The 
characteristic feature of 1B1 is its long H3 loop that 
inserts into the F´ pocket of CD1d, thereby 
preventing the closure of the F´ roof. The F´ roof is 
a hallmark and a major binding site for the CDR3a 
region of the Va14Vb8.2 TCR of Type I NKT 
cells. Since the H3 loop of 1B1 is deeply inserted 
into the CD1d groove, one side of the loop runs 
alongside the alkyl chain of a CD1d bound 
glycolipid. As alkyl chains generally do not differ 
greatly in structure for the various glycolipids, 1B1 
binding is not affected by the nature of the 
presented lipid. However, when considering other 
ligands, such as the hydrophobic peptide p99 or a 
cholesterol antigen, 1B1 binding may be greatly 
impaired or even abrogated (38,39). We showed the 
influence of lipid modifications in 1B1 binding 
using the a-galactosylsphingamide antigen 
aGSA[26,P5p]. The 1B1 Fab is unable to prevent 
Type I NKT cell activation using this antigen, 
suggesting that the binding affinity of 1B1 to CD1d 
presenting aGSA[26,P5p] is reduced below a 
threshold necessary for competing with TCR 
binding. However, when the intact IgG is used, 1B1 
is able to block activation, yet slightly less efficient. 
Together these data suggest that while 1B1 is a 
potent blocker of TCR mediated T cell activation 
for both Type I and Type II NKT cells, its binding 
strength to CD1d can be affected by the antigen that 
is presented by CD1d. This could result in a 
scenario where the activity of an antigen for NKT 
cells cannot be blocked by 1B1, leading to the 
incorrect assumption that the antigen activates NKT 
cells through a mechanism that does not involve 
TCR binding.




Glycolipid Ags –Bovine brain sulfatides and GT1b 
were purchased from Avanti Polar Lipids Inc.  C16 
a-GalCer, a-GSA[26,P5p] and C24:1-sulfatide 
were synthesized as previously reported (40-42).  
 
Cell line and cell culture - The hybridoma cell line 
expressing the rat anti-mouse IgG2b mAb 1B1 was 
grown in RPMI-1640 medium (Invitrogen, 
Carlsbad) supplemented with 10 mM HEPES pH 
7.5, 1% L-glutamine, 1% nonessential amino acids, 
1% Sodium Pyruvate 55 μM 2-mercaptoethanol, 20 
μg/ml gentamicin (Gibco) and 10% heat-
inactivated fetal calf serum (FCS). The hybridoma 
was maintained in an incubator with a humidified 
atmosphere containing 5% CO2 at 37 oC. 
 
Antibody production and purification. The 1B1 
hybridoma cells were gradually adapted to culture 
in protein-free hybridoma media (PFHM-II, 
Gibco), supplemented as indicated above. Cells 
from two T175 tissue culture flasks were 
transferred into one 2 L roller bottle, filled up to 1.5 
L with supplemented PFHM-II. Roller bottles were 
equilibrated with CO2 by placing in the 37ºC + 5% 
CO2 incubator with the lid loosened for 1/2-1 hour, 
then grown with closed lid at 37º C while rolling for 
approximately 2 weeks or until the media turned 
yellow. Cells were spun down (1250 rpm for 6 min) 
and supernatant was filtered (0.22µm) and 
concentrated to 300ml using a tangential flow 
through filtration unit (Millipore, Pellicon 2) while 
exchanging buffer to PBS. IgG was collected from 
supernatant using affinity chromatography using a 
5 ml HiTrap ProteinG column (GE Healthcare). 
IgG was eluted from the column with 0.1 M glycine 
pH 3.0, while 0.7 ml fractions were collected in 1.5 
ml test tubes containing 0.3 ml of 1M Tris pH 8.5 
for neutralization. IgG containing fractions were 
pooled and buffer exchanged against PBS using 
centrifugal filtration devices (Amicon Ultra, 
Millipore). Final yield of purified 1B1 IgG was 12 
mg/L of culture.  
 
Cloning and sequencing of 1B1 VH and VL genes – 
RNA isolation and sequencing was performed as 
reported previously for the a-GalCer specific mAb 
L363 (43), with some modifications including a 
poly-G tailing method (44). Briefly, total RNA was 
isolated from 5x106 hybridoma cells using the 
RNeasy Mini kit (Qiagen) according to the 
manufacturer’s instructions. First-strand cDNA 
synthesis of 5’RACE was performed according to 
the protocol for Clontech’s SMART-RACE using 
the Clontech cDNA amplification kit and the 
Invitrogen SuperScript II Reverse Transcriptase at 
42ºC for 50 min in a 20 µl reaction volume 
containing: 500 ng of total RNA, 0.6 µM 5’-RACE 
CDS Primer A, 0.6 µM SMART II A 
oligonucleotide, 1x RT buffer (20 mM Tris-HCl, 
pH 8.4, 50 mM KCl), 5 mM MgCl2, 0.01 M DTT 
and 4 U RNase out recombinant RNAse inhibitor. 
The first strand cDNA was then poly-G tailed using 
terminal deoxynucleotidyl transferase (TdT, 15U, 
Promega), 10 uM dGTP (GE healthcare), 1x 
reaction buffer (100 mM cacodylate buffer pH6.8, 
1 mM CoCl2 and 0.1 mM DTT; Promega) at 37 °C 
for 1 h. The TdT was then heat inactivated at 70 °C 
for 10 min. The tailed cDNA was amplified by PCR 
using a sense primer containing poly-C sequence 
and a rat IgG specific anti-sense primer (second 
strand reaction). For the PCR reaction, 48 µl of 
PCR mix containing 1x PCR buffer, 1.5 mM 
MgCl2, 0.2 mM dNTP, 1 µM ANCTAIL sense 
primer 5’-
cgtcgatgagctctagaattcgcatgtgcaagtccgatggtccccccc
ccccccc-3’, 1 µM ratκC643-rev antisense primer 5’-
aggatgatgtcttatgaacaa-3’, and 1.5 U high-fidelity 
Taq DNA polymerase were added to 2.5 µl cDNA 
(from the first-strand reaction) as suggested (45). 
The cycling profile used for the PCR was: 
denaturation at 94ºC for 30 seconds, annealing at 
60ºC for 30 seconds, extension at 72ºC for 3 min. 
At the end of the 30 cycles, a 10 min incubation step 
at 72ºC was done to complete elongation. The 
resulting PCR products were cloned into the 
pGEM-T easy vector (Promega) for sequencing. 
The VJ and VDJ gene rearrangement was 
determined as IGKV9S1*01 F/ IGKJ2-3*01 F 
(light chain) and IGHV5-25*01 F, IGHJ1*01 F, 
and IGHD1-6*01 F (heavy chain) using the IMGT 
server (46).  
 
Fab digestion and purification - Purified 1B1 mAb 
(rat IgG2b) at 1 mg/ml in PBS was incubated with 
1 % (w/w) activated papain (Sigma #P3125) and for 
3h at 37ºC in digestion buffer. Papain was activated 
by incubating 20 µl papain with 100 µl 10X papain 
buffer (1M NaOAc pH 5.5, 12 mM EDTA) and 100 
µl cysteine (12.2 mg/ml) for 15 min at 37ºC. The 
papain digestion was stopped by adding 20 mM 
Iodoacetamide (IAA). Digestion mix was 
concentrated and adjusted to PBS for subsequent 
protein A purification to remove undigested IgG 
and Fc. The protein A flow-through containing Fab 
was dialyzed against 20 mM NaOAc pH 5.5 
overnight and purified to homogeneity by cation-
exchange chromatography using MonoS (GE 
Healthcare).  
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Mouse CD1d/b2m expression in insect cells - The 
expression and purification methods of fully 
glycosylated mouse CD1d/b2m heterodimer 
proteins using the baculovirus expression system 
were reported previously (31,34,47). 
 
Gene cloning and site directed mutagenesis - 
cDNA of mouse CD1d (mCD1d) was subcloned 
into the E. coli expression vector pET-22b for 
subsequent expression in inclusion bodies. Single 
amino acid mutation C12S (TGC>TCC) was 
introduced into mCD1d using the Quick Change II 
site-directed mutagenesis kit (Stratagene) with 
primers C12S-forward (5’-
GAATTACACCTTCCGCTCCCTGCAGATGTC
TTCC-3’) and C12S-reverse (5’-
GGAAGACATCTGCAGGGAGCGGAAGGTGT
AATTC-3’). Successful mutation was verified by 
sequencing. Mouse beta2-microblobulin (b2M) 
without leader peptide was cloned into a separate 
pET-22b vector.   Synthetic DNA for wild type 1B1 
Fab and the 1B1 Fab mutant Y103K/I56S, which is 
unable to bind to mCD1d, was synthesized by 
Genscript and sub-cloned into the dual promoter 
vector pBACpHp10 with a C-terminal hexa-
histidine tag on the heavy chain and expressed in 
SF9 insect cells using the baculovirus expression 
system. SF9 cells were removed from the cell 
culture media by centrifugation, and the media was 
further concentrated to 0.3 liter and washed twice 
with PBS buffer. The protein was purified from the 
concentrated media by affinity chromatography on 
a Ni-NTA resin (Takara Bio.) in 50 mM Tris-HCl, 
300 mM NaCl, 250 mM Immidazole pH 8.0, 
followed by size-exclusion chromatography 
(Superdex S200 16/60 GL; GE Healthcare) in 50 
mM HEPES, pH 7.5, and 150 mM NaCl.  
 
Mouse CD1d refolding and purification –mCD1d 
and b2M were separately expressed in E. coli and 
purified from inclusion bodies as reported for Qa-
1a (48). The mCD1d-C12S/β2m complex was 
generated by refolding. First, 1 mg mCD1d and 2.4 
mg mβ2m denatured inclusion bodies were loaded 
into two separate 1 ml syringes. Next, mCD1d and 
mβ2m were injected into 100 ml high-speed stirred 
cold refolding buffer (400 mM L-arginine, 100 mM 
Tris-HCl pH 8.0, 2 mM EDTA, 5 mM reduced 
glutathione, 0.5 mM oxidized glutathione, and 0.2 
mM PMSF) through 26 gauge needles as close to 
the stirring bar as possible and incubated at 4 ˚C 
with medium-speed stirring. After 12 and 24 hours, 
additional 1mg mCD1d was added to the refolding 
reaction and continued to incubate until 72 hours 
under constant stirring. Finally, the refolding 
mixture was concentrated (Millipore Amicon 30K 
centrifugal filter) and purified by size exclusion 
chromatography on a Superdex S200 GL 10/300 in 
50 mM HEPES pH 7.5, 150 mM NaCl. Refolded 
mCD1d-C9S/β2m complex was analyzed by SDS-
PAGE. 
 
CD1d-1B1 Fab complex formation and 
crystallization - Refolded or insect cell expressed 
mCD1d was incubated with equimolar amounts of 
recombinantly expressed 1B1 Fab (method?) or 
1B1 Fab obtained by papain digestion for 4 hours at 
room temperature. The ternary mCD1d/1B1Fab 
complex was isolated by size exclusion 
chromatography using a Superdex S200 10/300 in 
50 mM HEPES pH 7.5, 150 mM NaCl and further 
concentrated to 3-4 mg/ml in 10 mM HEPES pH 
7.5, 30 mM NaCl for subsequent crystallization. 
Crystals were obtained in various combinations of 
CD1d and 1B1 Fab. 
 
Crystallization and structure determination - The 
initial crystals of recombinant 1B1 Fab and 
refolded mCD1d complexes were grown as small 
plates by mixing 200 nl precipitant (100 mM MES 
pH 6.5, 12% (w/v) PEG 20K) with 200 nl protein 
solution at 22 ̊C using the sitting drop vapor 
diffusion method and the liquid handling robot 
Phoenix (Art Robbins Instruments). Other 
combinations such as insect cell mCD1d and papain 
digested 1B1 Fab also yielded crystals but of 
limited diffraction power. The diffraction-quality 
plate-like crystals were manually optimized and 
obtained in 80 mM MES pH 6.5, 8-10% (w/v) PEG 
20K. Crystals were flash-cooled at 100 K in mother 
liquor containing 22% glycerol. Diffraction data 
were collected at the Stanford Synchrotron 
Radiation Laboratory (SSRL) beamline 9-2 and 
processed with HKL2000 (49). The 1B1 
Fab/mCD1d crystal belong to space group C2221 
with unit cell parameters a=84.05 Å; b=160.96 Å; 
c=165.42 Å. The asymmetric unit contains one 1B1 
Fab/mCD1d complex. The crystal structure was 
determined by molecular replacement using 
PHASER as part of the CCP4 suite (50,51). Protein 
coordinates from the mCD1d-iGb3 structure [PDB 
code 2Q7Y] (52) and the L363 Fab (PDB code 
3UBX) (43) were used as the search models for 
mCD1d and the 1B1 Fab, respectively. The phased 
model was rebuilt into sA-weighted 2Fo–Fc and Fo–
Fc difference electron density maps using the 
program COOT (53) and refined in REFMAC5 
(54). The complex structure was refined to 2.45 Å 
to an Rcryst and Rfree of 21.0% and 24.7% 
respectively. The quality of the model was 
  Structure of the mouse CD1d/1B1-Fab complex 
 7 
examined with the program Molprobity (55). Data 
collection and refinement statistics are presented in 
Table 1.  
 
Glycolipid loading and native isoelectric focusing 
(IEF) gel electrophoresis – For SPR or native IEF, 
10 µl (~5 µg) of insect cell expressed mouse CD1d 
was loaded overnight with 6-10 times molar excess 
of either C24:1 sulfatide, bovine brain sulfatides, or 
GT1b (dissolved at 5-10 mg/ml in DMSO) in 100 
mM HEPES pH 7.5, 150 mM NaCl without the 
addition of any detergents. Loading efficiency was 
analyzed via native IEF gel electrophoresis.  For 
each protein-lipid complex, 4 µl solution were 
loaded onto a 6 well pH 5-8 native IEF gel and 
analyzed via the PhastSystem (GE Healthcare).     
 
Surface plasmon resonance (SPR) studies. The 
real-time binding kinetics between 1B1 Fab and the 
CD1d-glycolipid complexes was analyzed by SPR 
using a Biacore T200 (Biacore, GE Healthcare) 
instrument. Briefly, insect cell expressed mCD1d 
protein containing a C-terminal birA-tag 
(LHHILDAQKMVWNHR) was enzymatically 
biotinylated and purified according to established 
methods (31,47). Biotinylated mCD1d was loaded 
with glycolipids overnight as reported above, and ≈ 
400 RU of the individual mCD1d-glycolipd 
complexes were immobilized on a CAP sensor chip 
(GE Healthcare). A series of increasing 
concentrations (3-fold dilutions from 1.1 – 90 nM) 
of 1B1 Fab were passed over the immobilized 
CD1d-glycolipid complexes at 25 °C with a flow 
rate of 30 μl/min in a single cycle kinetic 
experiment. For background subtraction, flow 
channel 1 was similarly prepared but no protein was 
immobilized and the binding response of 1B1 Fab 
to flow channel 1 was subtracted from the other 
flow channel. The experiments were performed at 
least twice and kinetic parameters were calculated 
using a simple Langmuir 1:1 model in the BIA 
evaluation software 
 
Cell free antigen presenting assay - APC free 
antigen presenting assay for stimulation of mouse 
iNKT cell hybridoma by soluble insect cell 
expressed mCD1d was carried out following 
published protocols (56,57). 96-well plates were 
coated with 1 µg of CD1d and incubated overnight 
at RT with 100 ng of glycolipids (1 µg/ml) in 
triplicates. Buffer was removed and indicated 
concentration of 1B1 Fab (0-100 µg) or 1B1 IgG 
(0-150 µg) in 50 µl or culture media added for 2 h 
at 37C.  Hybridoma cells (5x104 of either Type I 
NKT 1.2 or Type II NKT XV19) in 50 µl culture 
media were added to each well and co-incubated 
with CD1d-glycolipid complexes overnight at 37˚C 
in a CO2 incubator. IL-2 release in the APC free 
antigen-presenting assay was measured after 16 h 
of culture in a sandwich ELISA according to 
standard protocols to assess the extent to which 1B1 
blocked both Type I and Type II NKT cell 
activation. As a negative control, the 1B1 Fab 
double mutant Y103K/I56S that lost mouse CD1d 
binding was generated. 
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TABLES 
Table 1. Data collection and refinement statistics 
 
Data collection statistics mCD1d/1B1 
complex 
PDB ID  
Space group C2221 
Cell dimension  
a, b, c, (Å) 84.1, 161.0, 165.4 
a=b= g (˚) 90.00 




No. of unique reflections 41,732 (4,082) 
Rmeas (%) 8.1 (62.0) 
Rpim (%) 3.1 (25.0) 
Multiplicity 6.6 (5.9) 
Average I/σ 19.1 (1.8) 
Completeness (%) 99.7 (98.5) 
  
Refinement statistics  









R.m.s. deviations  
Bonds (Å) 0.005 
Angles (°) 1.37 
B-factors (Å2)  
Protein 59.6 
Water 49.1 
 Sodium 50.6 
Ligand 52.8 
R factor (%) 20.9 
Rfree (%) 24.4 
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Table 2. Comparison of Fab/TCR-mCD1d-glycolipid contacts  
Individual buried surface areas 
within the ternary complexes 










mCD1d  610 710 680 
glycolipid  110 160 150 
Fab VL/TCR Va  50 410 660 
Fab VH/TCR Vb  580 470 170 
Fab/TCR - CD1d 1,430 1,610 1,600 
a,b,c Values are calculated using PISA (58). b,c  Values from (43).  
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Table 3. Atomic contacts in the mCD1d-1B1-Fab complex 
 
CDR 1B1  Endogenous lipid Bonds 
H3 Leu106 UNK1 C8 VDW 
 Gly105 UNK1 C12 VDW 
 Tyr104 UNK1 C16 VDW 
CDR 1B1 mCD1d Bonds 
L1 Tyr31 Glu83 VDW 
H2 Asp55 Lys148 Salt bridge 
  Lys148 H bond 
 Ile56 Lys148 VDW 
  Val149 VDW 
  Leu145 VDW 
H3 Tyr103 Ala152 VDW 
  Asp153 VDW 
 Tyr104 Asp153 VDW 
 Gly105 Asp153 H bond 
  Leu150 VDW 
  Asp80 VDW 
  Val149 VDW 
 Leu106 Asp80 H bond 
  Leu84 VDW 
  Leu150 VDW 
  Pro146 VDW 
  Val149 VDW 
 Leu107 Val149 VDW 
  Asp80 VDW 
  Glu83 VDW 
 Leu108 Val149 VDW 
 Arg109 Asp80 Salt bridge 
The molecular interactions within the complex were analyzed using the program CONTACT 
(CCP4, 1994). The distance cut-offs used were 4 Å (van der Waals interactions, VDW), 3.5 Å 
(hydrogen bonds) and 4.5 Å (salt bridges).  
 
  





FIGURE 1. Structure of the mCD1d/ 1B1 Fab complex.  (A) Cartoon representation of 1B1 Fab (L chain 
in green, H chain in orange) bound across the a1 and a2 helices of mCD1d. (B) Interactions between 1B1 
H3 region and the binding groove residues of CD1d. (C) 1B1 H2 interactions with CD1d. (D) Light chain 
contacts with CD1d are restricted to L1, without direct polar interactions. (E) Footprint of 1B1 Fab on 
CD1d (grey molecular surface) colored by H and L chain. Heavy chain forms the majority of contacts, 
while the L chain barely contacts Arg79 (R79) and Glu83 (E83). Binding footprint of 1B1 is centered above 
the F´ pocket of CD1d.   
 
FIGURE 2. CDR H3 of 1B1 contacts the spacer lipid. (A) Three spacer molecules (yellow sticks with 
FoFc electron density map contoured at 3s) are bound in the CD1d binding groove (grey molecular surface, 
cut open). H3 residues as orange sticks with vdW interactions with the spacer molecule as black dashed 
lines. Note how deep Leu106 of H3 is inserted into the F´ pocket of CD1d. (B) Molecular model with 
sulfatide occupying the CD1d binding groove shows close contacts between the galactose headgroup and 
the H3 loop. (C) native IEF gel of insect cell expressed mCD1d (lane 1, band at 0) with fully loaded bovine 
brain sulfatides (lane 2, band at -1) or GT1b (lane 3, band at -3). (D) SPR sensorgram (single cycle kinetics) 
of 1B1 Fab to immobilized CD1d presenting the different CD1d-glycolipid complexes shown in panel C. 
Binding kinetics are not influenced by the nature of the lipid.  Kinetic values are indicated in each panel. 
(E) Binding response of 100 nM of wildtype 1B1 Fab or the 1B1 Fab Y103K/I56S double mutant to either 
human or mouse CD1d. 
 
FIGURE 3. Comparison between 1B1 Fab and Va14Vb8.2 TCR binding to CD1d. (A) Similar view as in 
Figure 2A illustrating how deep H3 (orange) of 1B1 is inserted into the F´ pocket of CD1d compared to 
CDR3a (cyan) of the TCR. PDB ID 3HE6 is shown for the CD1d-aGalCer-TCR complex, with the 1B1 
position overlayed.  The ligand aGSA[26,P5p] is superposed on aGalCer and reveals close contacts with 
Leu106H of 1B1. Hydrophobic fingers L106H and Leu99a are shown. (B) The different binding mode of 
both H3 and CDR3a lead to a different side chain orientation of the CD1d F´ pocket lining residues. CD1d 
residues from the 1B1 complex as grey sticks and those from the TCR complex as cyan sticks. (C) The long 
H3 loop prevents the F´ roof closure of CD1d, as it penetrates into the F´ pocket, while CDR3a of the TCR 
sits above the F´ pocket and binds above the closed F´ roof (D).  
 
FIGURE 4. 1B1 blocks both Type I and Type II NKT cell activation. (A) NKT cell hybridoma activation 
assay using CD1d coated plates presenting the lipids aGalCer, aGSA[26P5p], and sulfatide. Addition of 
1B1 Fab (top row) or 1B1 IgG (bottom row) reduces IL-2 production in a dose dependent manner (black 
bars). An engineered 1B1 Fab mutant that cannot bind to mCD1d or an isotype control IgG do not block 
NKT cell activation (grey bars). Middle columns indicate that 1B1 Fab is not able to block NKT cell 
activation by aGSA[26P5p], while 1B1 IgG retains blocking, albeit at a slightly higher IgG concentration. 
Each experiment has been performed twice with each measurement in triplicate. Standard deviation is 
shown with error bars. (B) CD1d binding footprint of the individual TCRs (2C12 and XV19) and 1B1 Fab 
are shown for comparison. Residues Ser76 (S76) and Arg79 (R79) are shared contact residues of CD1d and 
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Figure 2  
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Figure 4 
 
 
